Vishangi Dave
Experienced in Childhood Acute Myeloid Leukemia

Dr. Vishangi Dave

Otolaryngology | Oncology | Hematology
13041 North Del Webb Boulevard, Suite 200, 
Sun City, AZ 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Childhood Acute Myeloid Leukemia
13041 North Del Webb Boulevard, Suite 200, 
Sun City, AZ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

I enjoy spending time with family and friends, hiking, gardening.

Dr. Dave is rated as an Experienced provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. Her top areas of expertise are Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Richter Syndrome, and Familial Prostate Cancer.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Pramukhswami Medical College, 2010
Residency
South Brooklyn Health, Internal Medicine, 2015
Specialties
Otolaryngology
Oncology
Hematology
Licenses
Internal Medicine in AZ
Board Certifications
American Board Of Internal Medicine/Medical Oncology
American Board Of Internal Medicine
American Board Of Internal Medicine/Hematology
Fellowships
Maimonides Medical Center, Hematology/Oncology, 2018
Hospital Affiliations
Banner Boswell Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Banner MD Anderson Cancer Center Medical Oncology Clinic
13041 North Del Webb Boulevard, Suite 200, Sun City, AZ 85351

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations
Enrollment Status: Recruiting
Publish Date: December 11, 2025
Intervention Type: Procedure, Drug, Biological, Other
Study Drugs: Gemcitabine, Cisplatin, Pegfilgrastim
Study Phase: Phase 2
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Suspended
Publish Date: December 17, 2025
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups
Enrollment Status: Active_not_recruiting
Publish Date: December 03, 2025
Intervention Type: Drug, Biological
Study Drugs: Axitinib, Nivolumab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2025
Intervention Type: Drug, Other, Biological
Study Drugs: Dasatinib, Imatinib Mesylate, Nilotinib, Pembrolizumab
Study Phase: Phase 2
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: September 23, 2025
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

3 Total Publications

Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer.
Clinical benefit and tolerability of adjuvant intraperitoneal chemotherapy in patients who have or have not received neoadjuvant chemotherapy for advanced ovarian cancer.
Journal: World journal of clinical oncology
Published: January 03, 2019
Similar Doctors
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Abraham S. Kanate
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Abraham S. Kanate
Hematology Oncology | Hematology | Oncology

Honorhealth

7400 E Osborn Rd, 
Scottsdale, AZ 
 (22.2 miles away)
480-882-4000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Abraham Kanate is a Hematologist Oncology specialist and a Hematologist in Scottsdale, Arizona. Dr. Kanate is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Kanate is currently accepting new patients.

Distinguished in Childhood Acute Myeloid Leukemia
Dr. Matthew L. Ulrickson
Hematology Oncology | Hematology | Oncology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Matthew L. Ulrickson
Hematology Oncology | Hematology | Oncology

Banner Cancer Center Specialists LLC

1900 N Higley Rd, 
Gilbert, AZ 
 (35.7 miles away)
480-543-2000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Matthew Ulrickson is a Hematologist Oncology specialist and a Hematologist in Gilbert, Arizona. Dr. Ulrickson is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Ulrickson is currently accepting new patients.

Distinguished in Childhood Acute Myeloid Leukemia
Dr. Ryan Robetorye
Hematology
Distinguished in Childhood Acute Myeloid Leukemia
Dr. Ryan Robetorye
Hematology

Mayo Clinic Hospital In Arizona

5777 E Mayo Blvd, 
Phoenix, AZ 
 (19.2 miles away)
480-342-3670
Languages Spoken:
English
See accepted insurances

Ryan Robetorye is a Hematologist in Phoenix, Arizona. Dr. Robetorye is rated as a Distinguished provider by MediFind in the treatment of Childhood Acute Myeloid Leukemia. His top areas of expertise are Acute Myelomonocytic Leukemia, Richter Syndrome, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dave's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 80 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile